Market Place
Sourcing Support
Tiziana Life Sciences Announces Late-Breaking Poster at WPC
14 Apr 2026 //
GLOBENEWSWIRE
Tiziana Announces Nasal Foralumab Immunologic Analysis
21 Jul 2025 //
GLOBENEWSWIRE
Tiziana Signs Product Development Deal With Renaissance Lakewood
21 Feb 2025 //
GLOBENEWSWIRE
Tiziana Life Sciences Shows Positive Results In Spinal Cord Injury
23 Jan 2025 //
PHARMAWEB
Tiziana Life Sciences To Avoid Immediate Capital Raising Activities
23 Jan 2025 //
GLOBENEWSWIRE
Tiziana Life Announces ALS Trial Grant from ALS Association
19 Nov 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences Granted FDA Fast Track Designation
24 Jul 2024 //
GLOBENEWSWIRE
Tiziana Receives $3.4 Million in Non-Dilutive Funding
28 Jun 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences To Dose First Alzheimer`s Patient
26 Jun 2024 //
GLOBENEWSWIRE
FDA Accepts Tiziana Life Fast Track Designation Submission for Treatment of MS
11 Jun 2024 //
GLOBENEWSWIRE
Tiziana Board Chair To Receive MS Research Award
30 May 2024 //
GLOBENEWSWIRE
Tiziana`s MS Patients Show More Expanded Access Improvements
22 Apr 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Podium Presentation
05 Mar 2024 //
GLOBENEWSWIRE
Tiziana Life Files New Patent Application for Combination Therapy of anti-CD3
05 Jan 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich
01 Nov 2023 //
GLOBENEWSWIRE
Tiziana Life to Participate in H.C. Wainwright 25th Annual Investment Conference
08 Sep 2023 //
GLOBENEWSWIRE
Tiziana Appoints William A. Clementi as Chief Development Officer
23 Aug 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
21 Jul 2023 //
GLOBENEWSWIRE
Tiziana Life Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
13 Jun 2023 //
GLOBENEWSWIRE
Tiziana Announces Participation on Webull Corporate Communications Platform
23 May 2023 //
GLOBENEWSWIRE
Tiziana Announces Findings from Anti-CD3 mAb
27 Apr 2023 //
PRESS RELEASE
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months
26 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
24 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Presentations on Intranasal Foralumab at the Conference
10 Apr 2023 //
GLOBENEWSWIRE
Tiziana Announces Invitation for Presentation on Anti-CD3 mAb
04 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Anti-CD3 mAb Research for Alzheimer’s Disease
31 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life to Proceed with PII Trial in Patients with Non-Active SPMS
28 Mar 2023 //
GLOBENEWSWIRE
Tiziana Announces Purchase of Common Shares by Chairman and Acting CEO
22 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Purchase of Common Shares by Chairman and Acting CEO
21 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Purchase of Common Shares by Chairman and Acting CEO
20 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Highlighted in Forbes Article
17 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Purchase of Common Shares by Chairman and Acting CEO
17 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces IND filed for Phase 2 of Milciclib with Gemcitabine
04 Jan 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Additional Clinical Improvements in Second Patient
03 Jan 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Updated Interim Results for the 6 Months Ended 30 June
29 Dec 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Interim Results for the Six Months Ended 30 June 2022
27 Dec 2022 //
GLOBENEWSWIRE
Tiziana to Participate in January Investor Meetings
16 Dec 2022 //
GLOBENEWSWIRE
Tiziana Announces Completion of Prerequisite Pre-Clinical Safety Study
15 Dec 2022 //
GLOBENEWSWIRE
Tiziana Granted 180-day Extension by Nasdaq to Meet Bid Price Requirements
14 Dec 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Date of Annual General Meeting 2022
06 Dec 2022 //
GLOBENEWSWIRE
Tiziana Announces Publication of Article on Foralumab
23 Nov 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Near Strategic Focus on Intranasal Foralumab
10 Nov 2022 //
GLOBENEWSWIRE
Tiziana prioritizes lowest hanging fruit, shelves unripe assets
10 Nov 2022 //
FIERCEBIOTECH
Tiziana Completes Enrollment of the First Patient to Evaluate Foralumab
02 Nov 2022 //
GLOBENEWSWIRE
Tiziana Starts Enrollment of the First Patient to Evaluate Foralumab
26 Oct 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
19 Oct 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Plans to Submit IND for Ph1 Trial of Intranasal Foralumab
12 Oct 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the
28 Sep 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Continued Clinical Imp in the Second Patient
20 Sep 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
16 Sep 2022 //
GLOBENEWSWIRE
Tiziana Announces Purchase of Common Shares by Chief Medical Officer
09 Sep 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
25 Aug 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
17 Aug 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Presentation at AAIC 2022
01 Aug 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as CMO and Acting CSO
18 Jul 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Resignation of CEO
15 Jul 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
17 Jun 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
09 Jun 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Interview on Improvements for 2nd SPMS Patient
09 Jun 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Positive Results in Second Patient with SPMS
08 Jun 2022 //
GLOBENEWSWIRE
